L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

A new report has laid bare how head and neck cancers have "persistently poor" survival rates in our region.

LOUISVILLE, Ky. (WDRB) -- According to the American Cancer Society, people with cancer are living longer than ever before. The organization credited large advancements in cancer research. "This is one ...

Head and neck cancer (HNC) represents a significant global health challenge, characterized by aggressive local invasion, frequent recurrence, and poor survival rates. Beyond its physical burden, HNC ...

Enfortumab vedotin and pembrolizumab showed a 39% overall response rate in recurrent/metastatic HNSCC with PD-L1 CPS ≥1. The trial reported a 9.8% complete response rate and a 29.3% partial response ...

Less-invasive robotic surgery for upper airway and digestive track malignant tumors is as effective as other minimally invasive surgical techniques based on patient function and survival, according to ...

Bicara Therapeutics (NASDAQ:BCAX) outlined its clinical and development strategy for its lead bifunctional antibody program, FICERA, during a presentation and fireside chat at TD Cowen’s 46th annual ...

While mortality rates are at record lows, experts warn that certain cancers are increasing—especially among younger adults.